Forest plot displaying the effect estimates comparing azithromycin and placebo treatment in subgroups defined by above (>0.39 ng·mL−1) or below (<0.39 ng·mL−1)

Slides:

Advertisements

Similar presentations

Least squares (LS) mean change from baseline (95% CI) in trough forced expiratory volume in 1 s (FEV1) according to chronic obstructive pulmonary disease.

Advertisements

The 20-year overall survival was significantly higher in the newborn screening (NBS) group than in the symptoms group for each of the subgroups defined.

Echocardiography view

Bland–Altman plot of projected apnoea threshold of measurement 1 versus 2. a) Rebreathing (R) method (n=20); b) steady-state (SS) method (n=18). Bland–Altman.

Kaplan–Meier curves of 12-month survival after an index chronic obstructive pulmonary disease-related hospitalisation according to level of moderate and.

Change from baseline in trough forced expiratory volume in 1 s (FEV1) (per-protocol population). Change from baseline in trough forced expiratory volume.

Prevalence of true-positive, false-negative and false-positive cases of chronic obstructive pulmonary disease identified with the fixed-limit Global Initiative.

Bland–Altman plots of in vitro functional residual capacity (FRC) measurements on each device. Bland–Altman plots of in vitro functional residual capacity.

A) CT scan of patient number 1, before pembrolizumab; b) CT scan of patient number 1, after 11 pembrolizumab infusions; c) CT scan of patient number 1,

Survival without tracheostomy

Effects of reslizumab on: (a) clinical asthma exacerbation (CAE) rates; (b) rates of clinical asthma exacerbation requiring oral corticosteroids (OCS);

Kaplan–Meier curve for the time until the development of lung cancer in patients with idiopathic pulmonary fibrosis. Kaplan–Meier curve for the time until.

A) Exhaled nitric oxide fraction (FeNO) before and after 9 weeks of treatment; b) percentage change in forced expiratory volume in 1 s (FEV1) following.

Bland–Altman plot of slopes of measurement 1 versus 2

Least squares (LS) mean change from baseline (95% CI) in St George's Respiratory Questionnaire (SGRQ) Total score according to exacerbation history (intent-to-treat.

Effects of reslizumab on asthma quality of life questionnaire (AQLQ) score in Global Initiative for Asthma (GINA) Step 4 and 5 patients. Effects of reslizumab.

Change from baseline following beclomethasone/formoterol and placebo in a) platelet–monocyte aggregate formation, b) P-selectin expression and c) platelet.

A) Evolution of the yearly mortality rate from year 1 to year 15 of simulation according to the operating rule and to the scenario of organ scarcity. b)

Venn diagram showing the overlap between the various chronic obstructive pulmonary disease (COPD) diagnoses: self-reported physician-diagnosed, fixed ratio.

Examination of the prevalence of asthma exacerbations and loss of asthma control throughout pregnancy in women with asthma. Examination of the prevalence.

a–h) Examples of short frenula in children and teenagers.

Predictors of disease progression in patients with CKD

In vitro quantification of exon skipping associated with 15 premature termination codons using minigenes. In vitro quantification of exon skipping associated.

Effects of reslizumab on asthma control questionnaire-7 (ACQ-7) score in Global Initiative for Asthma (GINA) Step 4 and 5 patients. Effects of reslizumab.

Discriminatory performance (receiver operating characteristics (ROC) analysis) of lung clearance index (LCI) analysed with the different methods. a) ROC.

A white elephant or the elephant in the room

Swimmer plots showing post-nivolumab progression-free survival for the three main drugs studied according to the line of treatment in which they were received.

Forest plot showing the number of adults (at the top) and children (lower down) who were admitted to hospital after treatment in the emergency department.

Least squares (LS) mean change from baseline (95% CI) in St George's Respiratory Questionnaire (SGRQ) Total score according to chronic obstructive pulmonary.

An audit of the post-hospitalisation pulmonary rehabilitation pathway in a northwest London hospital. An audit of the post-hospitalisation pulmonary rehabilitation.

The variability of probability of that the length of stay is longer than the median by country. The variability of probability of that the length of stay.

Comparison of absolute counts for a, b) white blood cells (WBC), c, d) neutrophils, e, f) monocytes, and g, h) eosinophils for 100 patients with lymphangioleiomyomatosis.

Most frequent words and phrases based on user comments about the registry. Most frequent words and phrases based on user comments about the registry. Word.

Portions of two representative reports, a, c and e) one during noninvasive ventilation through a helmet and b, d and f) the other through mask. Portions.

Least squares (LS) mean change from baseline (95% CI) in trough forced expiratory volume in 1 s (FEV1) according to exacerbation history (intent-to-treat.

Forest plot of the effect of “add-on” therapies on 6-min walking distance change (in metres). Forest plot of the effect of “add-on” therapies on 6-min.

Intensity of statistical methods and reporting subdivided by the journal groups. Intensity of statistical methods and reporting subdivided by the journal.

Concentration of inflammatory cytokines in epithelial lining fluid (ELF) were plotted for the normal control, smoker normal forced oscillation technique.

Systems biology as a tool to improve idiopathic pulmonary fibrosis (IPF) treatment effectiveness. Systems biology as a tool to improve idiopathic pulmonary.

Flow–volume loop analysis

a) Mortality per time point (p<0

Evaluation by high-resolution computed tomography (HRCT).

Scatter plot of the % change versus baseline in pulmonary function test results at a) 4 months and b) the end of the study versus the analyte concentration.

Venn diagram showing the overlap between the various spirometric definitions of airway obstruction and respiratory symptoms. **: p

Schematic overview of the suggested pharmacological management of chronic obstructive pulmonary disease (COPD). Schematic overview of the suggested pharmacological.

Forest plots for randomised and cluster randomised controlled trials from Cochrane review Biomarkers as point-of-care tests to guide prescription of antibiotics.

Time to disease progression or death in a) the whole Bosentan Use in Interstitial Lung Disease (BUILD)-1 study population and b) the subpopulation with.

The regression lines between the asynchrony index (AI) and the double true index (DTI) shown for overall data, and for mask and helmet separately. The.

Forest plot of adjusted odds ratios (with 95% confidence intervals) from multivariable multinomial logistic regression analysis (table 4), by number of.

Receiver operating characteristic (ROC) curves (area under the curve (AUC) (95% CI)) for FACED (forced expiratory volume in 1 s, age, chronic colonisation.

Concordance of review article recommendations with contemporary guidelines. Concordance of review article recommendations with contemporary guidelines.

Felix Ratjen, Todd Durham, Tomas Navratil, Amy Schaberg, Frank J

Weekly pneumococcal community-acquired pneumonia incidence rates over 5 years, with delineated school holiday periods by year. a) Year 1 (September 2008–2009).

Differences in a) functional residual capacity (FRC) and b) lung clearance index (LCI) when using all trials in comparison with only the first two trials.

Scatter plot of body mass index (BMI) versus forced expiratory volume in the first second (FEV1), and linear correlation lines for normal spirometry and.

Physician perspectives on self-administration of i. v. α1-antitrypsin

Overall forest plot from meta-analysis carried out in 11 studies a) assessing the relative risk of adverse events; and subgroup analysis performed on studies.

Distribution of patients in the first- or second-year follow-up according to the number of acute exacerbations of chronic obstructive pulmonary disease.

Post-operative a) neutrophil counts, but not b) lymphocyte or c) platelet counts, were higher in current smokers than ex-smokers. #: time-points were statistically.

Change in the regular use of inhaled corticosteroids (as a single inhaler or in combination; any use in the last 12 months) in participants with persistent.

Percentage of culture-positive or PCR-positive sputum samples at stable state and exacerbation in year 1 and year 2 (full cohort, year 1 or year 2). a)

Forest plot and pooled estimates of the effect of NAFLD on the risk of incident diabetes in 16 eligible studies, stratified by length of follow-up (FU)

Forest plot from meta-analysis carried out on four studies including high-dose N-acetylcysteine (NAC) treatment a) assessing the relative risk of chronic.

Effect of the presence of aetiological factors (bacterial or viral infection, or eosinophilic inflammation) at stable visits on the odds of experiencing.

Composition of the most common clusters at the a) onset of the first acute respiratory tract infection (swab A) and b) 3 weeks later (swab B) illustrated.

A response-adaptive platform trial may start by enrolling a broad patient population and randomise patients equally across a range of treatments, shown.

Effects of reslizumab on lung function (forced expiratory volume in 1 s; FEV1) in Global Initiative for Asthma (GINA) Step 4 and 5 patients. Effects of.

Percentage of positive results by pathogen among study patients with identified pathogens. “Other” includes respiratory viruses, Stenotrophomonas, Prevotella,

Comparison of exhaled H2O2 values in chronic obstructive pulmonary disease (COPD) patients (n=12) and control group (n=9). a) Raw ambient air concentrations.

Median (95% CI) exhaled nitric oxide fraction (FeNO) at each visit for the two intervention groups. Median (95% CI) exhaled nitric oxide fraction (FeNO)

Presentation transcript:

Forest plot displaying the effect estimates comparing azithromycin and placebo treatment in subgroups defined by above (>0.39 ng·mL−1) or below (<0.39 ng·mL−1) the median level of serum desmosine for the COLUMBUS trial population. Forest plot displaying the effect estimates comparing azithromycin and placebo treatment in subgroups defined by above (>0.39 ng·mL−1) or below (<0.39 ng·mL−1) the median level of serum desmosine for the COLUMBUS trial population. The effect estimate shown is incident rate ratio for frequency of exacerbations, severe exacerbations and moderate exacerbations, and hazard ratio for time to first exacerbation. James D. Chalmers et al. ERJ Open Res 2018;4:00136-2018 ©2018 by European Respiratory Society